JP2020512382A - Ｐｄ−ｌ１抗体およびｔａ−ｍｕｃ１抗体 - Google Patents

Ｐｄ−ｌ１抗体およびｔａ−ｍｕｃ１抗体 Download PDF

Info

Publication number
JP2020512382A
JP2020512382A JP2019553811A JP2019553811A JP2020512382A JP 2020512382 A JP2020512382 A JP 2020512382A JP 2019553811 A JP2019553811 A JP 2019553811A JP 2019553811 A JP2019553811 A JP 2019553811A JP 2020512382 A JP2020512382 A JP 2020512382A
Authority
JP
Japan
Prior art keywords
antibody
gex
pdl
cells
fucose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019553811A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020512382A5 (enExample
Inventor
パトリック ケーラー
パトリック ケーラー
ステッフェン ゴレッツ
ステッフェン ゴレッツ
アンティエ ダニエルクザイク
アンティエ ダニエルクザイク
ジョアンナ ルーマン
ジョアンナ ルーマン
クリストフ ゴレッツ
クリストフ ゴレッツ
Original Assignee
グリコトープ ゲーエムベーハー
グリコトープ ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グリコトープ ゲーエムベーハー, グリコトープ ゲーエムベーハー filed Critical グリコトープ ゲーエムベーハー
Publication of JP2020512382A publication Critical patent/JP2020512382A/ja
Publication of JP2020512382A5 publication Critical patent/JP2020512382A5/ja
Priority to JP2022195338A priority Critical patent/JP2023025215A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2019553811A 2017-03-29 2018-03-28 Ｐｄ−ｌ１抗体およびｔａ−ｍｕｃ１抗体 Pending JP2020512382A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022195338A JP2023025215A (ja) 2017-03-29 2022-12-07 Ｐｄ－ｌ１抗体およびｔａ－ｍｕｃ１抗体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
LU100150 2017-03-29
LULU100150 2017-03-29
EP17171013.0 2017-05-15
EP17171013 2017-05-15
PCT/EP2018/057844 WO2018178122A1 (en) 2017-03-29 2018-03-28 Pd-l1 and ta-muc1 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022195338A Division JP2023025215A (ja) 2017-03-29 2022-12-07 Ｐｄ－ｌ１抗体およびｔａ－ｍｕｃ１抗体

Publications (2)

Publication Number Publication Date
JP2020512382A true JP2020512382A (ja) 2020-04-23
JP2020512382A5 JP2020512382A5 (enExample) 2021-05-06

Family

ID=61965929

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019553811A Pending JP2020512382A (ja) 2017-03-29 2018-03-28 Ｐｄ−ｌ１抗体およびｔａ−ｍｕｃ１抗体
JP2022195338A Pending JP2023025215A (ja) 2017-03-29 2022-12-07 Ｐｄ－ｌ１抗体およびｔａ－ｍｕｃ１抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022195338A Pending JP2023025215A (ja) 2017-03-29 2022-12-07 Ｐｄ－ｌ１抗体およびｔａ－ｍｕｃ１抗体

Country Status (7)

Country Link
US (1) US20200148785A1 (enExample)
EP (1) EP3601349A1 (enExample)
JP (2) JP2020512382A (enExample)
CN (1) CN111315776A (enExample)
AU (1) AU2018241916A1 (enExample)
CA (1) CA3057758A1 (enExample)
WO (1) WO2018178122A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200016899A (ko) 2017-06-01 2020-02-17 싸이톰스 테라퓨틱스, 인크. 활성화가능 항-pdl1 항체, 및 이의 이용 방법
CN111819203A (zh) 2018-03-01 2020-10-23 葛莱高托普有限公司 包含抗muc1抗体和il-15的融合蛋白构建体
SG11202010496WA (en) 2018-05-18 2020-12-30 Daiichi Sankyo Co Ltd Anti-muc1 antibody-drug conjugate
BR112021005365A2 (pt) * 2019-04-26 2021-11-16 I Mab Biopharma Us Ltd Anticorpo ou fragmento de ligação ao antígeno do mesmo, anticorpo biespecífico, composição, um ou mais polinucleotídeos, célula isolada, método para tratar câncer ou infecção, e, uso do anticorpo ou fragmento do mesmo ou da composição
KR20220119694A (ko) * 2019-12-23 2022-08-30 마크로제닉스, 인크. 암 치료를 위한 요법
IL272389A (en) 2020-01-30 2021-08-31 Yeda Res & Dev Kits containing antibodies to PD-L1 and their uses in therapy
WO2022028608A1 (zh) * 2020-08-07 2022-02-10 百奥泰生物制药股份有限公司 抗pd-l1抗体及其应用
AR133427A1 (es) 2023-07-31 2025-09-24 Sanofi Sa Anticuerpos anti-gprc5d y composiciones

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005035586A1 (ja) * 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. 融合蛋白質組成物
JP2005532253A (ja) * 2001-10-25 2005-10-27 ジェネンテック・インコーポレーテッド 糖タンパク質組成物
JP2017507900A (ja) * 2013-12-17 2017-03-23 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニスト及び抗ｈｅｒ２抗体を使用してｈｅｒ２陽性がんを治療する方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2807767B1 (fr) * 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
PT2073842E (pt) * 2006-09-10 2015-04-07 Glycotope Gmbh Utilização de células humanas provenientes de uma leucemia mielóide para expressão de anticorpos
EP2281844A1 (en) * 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies
RS61033B1 (sr) * 2011-11-28 2020-12-31 Merck Patent Gmbh Antitela na pd-l1 i njihova upotreba
US20150166664A1 (en) * 2012-07-18 2015-06-18 Glycotope Gmbh Novel therapeutic treatments with anti-her2 antibodies having a low fucosylation
EA201591977A1 (ru) * 2013-04-22 2016-06-30 Гликотоп Гмбх Противораковая терапия анти-egfr антителами, имеющими низкое фукозилирование
AR097584A1 (es) * 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005532253A (ja) * 2001-10-25 2005-10-27 ジェネンテック・インコーポレーテッド 糖タンパク質組成物
WO2005035586A1 (ja) * 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. 融合蛋白質組成物
JP2017507900A (ja) * 2013-12-17 2017-03-23 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニスト及び抗ｈｅｒ２抗体を使用してｈｅｒ２陽性がんを治療する方法

Also Published As

Publication number Publication date
US20200148785A1 (en) 2020-05-14
EP3601349A1 (en) 2020-02-05
CA3057758A1 (en) 2018-10-04
WO2018178122A1 (en) 2018-10-04
AU2018241916A1 (en) 2019-10-17
JP2023025215A (ja) 2023-02-21
CN111315776A (zh) 2020-06-19

Similar Documents

Publication Publication Date Title
JP7765397B2 (ja) 新規抗ｌｉｌｒｂ４抗体および派生産物
JP2023025215A (ja) Ｐｄ－ｌ１抗体およびｔａ－ｍｕｃ１抗体
AU2018344416B2 (en) IgG1 Fc mutants with ablated effector functions
CN110997712B (zh) 特异性结合pd-1的抗体及其使用方法
CA2512729C (en) Identification and engineering of antibodies with variant fc regions and methods of using same
JP7638935B2 (ja) 抗ｃｃｒ８抗体
JP2023511482A (ja) Ｃｄ２７６抗原の抗体ターゲティング、および他のモジュレーター、ならびにその使用
WO2021127088A1 (en) Materials and methods for in vivo biological targeting
TW202304987A (zh) 包含cd3抗原結合域之蛋白質及其用途
TW202304988A (zh) 靶向ＣＤ７９ｂ、ＣＤ２０、及ＣＤ３之三特異性抗體
WO2018178123A1 (en) BISPECIFIC MUC-1 x PD-L1 ANTIBODIES
EP3692059A1 (en) Cd3/cd33 bispecific binding molecules
WO2022201052A1 (en) Antibody targeting cd22 and cd79b
AU2012202125B2 (en) Humanized Anti-Interleukin 3 Receptor Alpha Chain Antibodies
WO2025180665A1 (en) Antibodies binding to cd2, and multifunctional molecules comprising such antibodies
TW202210510A (zh) 包含ｃｄ３抗原結合域之蛋白質及其用途
WO2025151607A1 (en) Methods and compositions for treating autoimmune, allergic and inflammatory diseases
HK40100657B (en) Anti-ccr8 antibodies
WO2022098910A1 (en) Icos antibodies for treatment of lymphomas

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190927

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210326

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210326

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220415

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220808